Brand drug maker representatives met with CMS and White House budget officials to push for higher Medicare hospital inpatient reimbursement through changes to the MS-DRG system and the New Technology Add-on Payments, about which industry has raised concerns for years. The Feb. 23 meeting was attended by industry representatives from the Biotechnology Innovation Organization -- which requested the meeting -- Gilead Sciences, Kite Pharma, Johnson & Johnson and Celgene. They discussed next year's proposed hospital inpatient pay rule, according to...